| RS2540810434 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2540813559 |
PAK1
|
Health Risk |
Likely pathogenic |
PAK1-related disorder, PAK1-related disorder |
| RS2540830069 |
PAK1
|
Health Risk |
Likely pathogenic |
PAK1-related disorder, PAK1-related disorder |
| RS2540830299 |
PAK1
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2540837488 |
SMARCC2
|
Health Risk |
Pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540854316 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2540862725 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540862808 |
PUS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540869203 |
FGD4
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 4, Charcot-Marie-Tooth disease type 4 |
| RS2540869432 |
PFKM
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type VII |
| RS2540870135 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540870148 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540870188 |
PUS1
|
Health Risk |
Pathogenic |
Myopathy, lactic acidosis |
| RS2540870199 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540870223 |
PFKM
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type VII |
| RS2540870266 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540870275 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540870285 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540870303 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540872758 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540872831 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540873106 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540873281 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540873437 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540873492 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540873523 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540873585 |
PUS1
|
Health Risk |
Likely pathogenic |
Myopathy, lactic acidosis |
| RS2540873599 |
PUS1
|
Health Risk |
Pathogenic |
Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B, Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B |
| RS2540873640 |
PUS1
|
Health Risk |
Pathogenic |
— |
| RS2540874019 |
PUS1
|
Health Risk |
Likely pathogenic |
PUS1-related disorder, Myopathy |
| RS2540881892 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540882312 |
FANCC
|
Health Risk |
Likely pathogenic |
— |
| RS2540882734 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540882833 |
ATP2B1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2540882993 |
SMARCC2
|
Health Risk |
Pathogenic |
— |
| RS2540883016 |
MYRF
|
Health Risk |
Pathogenic |
Cardiac-urogenital syndrome, Cardiac-urogenital syndrome |
| RS2540883356 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540883406 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2540884610 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540886440 |
FANCC
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2540886717 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540887710 |
FANCC
|
Health Risk |
Pathogenic/Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group C |
| RS2540887817 |
ABCC9
|
Health Risk |
Pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2540888580 |
FANCC
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Hereditary cancer-predisposing syndrome |
| RS2540889666 |
ACBD5
|
Health Risk |
Likely pathogenic |
— |
| RS2540892544 |
MYRF
|
Health Risk |
Pathogenic |
MYRF-related disorder, MYRF-related disorder |
| RS2540896084 |
SMARCC2
|
Health Risk |
Likely pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540898617 |
SPTAN1
|
Health Risk |
Pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2540899502 |
PFKM
|
Health Risk |
Pathogenic |
Glycogen storage disease, type VII |
| RS2540899815 |
SPTAN1
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy, 5 |
| RS25409 |
GABRB3
|
Health Risk |
Conflicting classifications of pathogenicity |
Epilepsy, childhood absence |
| RS2540900727 |
SMARCC2
|
Health Risk |
Likely pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540900784 |
SMARCC2
|
Health Risk |
Pathogenic |
— |
| RS2540901234 |
SMARCC2
|
Health Risk |
Likely pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540901407 |
PFKM
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type VII |
| RS2540901723 |
PFKM
|
Health Risk |
Likely pathogenic |
Glycogen storage disease, type VII |
| RS2540914599 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540915025 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540915033 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540915557 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540915931 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540915933 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540916075 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540916709 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540916726 |
CYP27B1
|
Health Risk |
Likely pathogenic |
— |
| RS2540916851 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540917035 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540917266 |
SMARCC2
|
Health Risk |
Conflicting classifications of pathogenicity |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540917461 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540917506 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540917603 |
CYP27B1
|
Health Risk |
Pathogenic |
— |
| RS2540919542 |
CYP27B1
|
Health Risk |
Pathogenic |
Vitamin D-dependent rickets, type 1A |
| RS2540924412 |
SMARCC2
|
Health Risk |
Pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540924441 |
SMARCC2
|
Health Risk |
Pathogenic |
Coffin-Siris syndrome 8, Coffin-Siris syndrome 8 |
| RS2540929867 |
MYRF
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2540930253 |
MYRF
|
Health Risk |
Likely pathogenic |
MYRF-related disorder, MYRF-related disorder |
| RS2540930729 |
SPTAN1
|
Health Risk |
Pathogenic |
— |
| RS2540935832 |
SMARCC2
|
Health Risk |
Pathogenic |
— |
| RS2540942755 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540942894 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540942936 |
TSFM
|
Health Risk |
Pathogenic |
— |
| RS2540943012 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540943113 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540943169 |
TSFM
|
Health Risk |
Pathogenic |
— |
| RS2540943259 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540943285 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540946087 |
MYRF
|
Health Risk |
Likely pathogenic |
Cardiac-urogenital syndrome, Cardiac-urogenital syndrome |
| RS2540948158 |
FANCC
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Fanconi anemia complementation group C |
| RS2540948320 |
FANCC
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2540948713 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540949104 |
TSFM
|
Health Risk |
Pathogenic/Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540949341 |
TSFM
|
Health Risk |
Pathogenic |
— |
| RS2540949362 |
MYRF
|
Health Risk |
Likely pathogenic |
MYRF-related disorder, MYRF-related disorder |
| RS2540949591 |
FANCC
|
Health Risk |
Likely pathogenic |
Fanconi anemia complementation group C, Fanconi anemia complementation group C |
| RS2540950794 |
TSFM
|
Health Risk |
Pathogenic |
— |
| RS2540950814 |
TSFM
|
Health Risk |
Likely pathogenic |
Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3, Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3 |
| RS2540951027 |
TSFM
|
Health Risk |
Pathogenic |
— |
| RS2540953908 |
MYRF
|
Health Risk |
Pathogenic |
Encephalitis/encephalopathy, mild |
| RS2540954215 |
MYRF
|
Health Risk |
Conflicting classifications of pathogenicity |
Cardiac-urogenital syndrome, Cardiac-urogenital syndrome |
| RS2540954236 |
MYRF
|
Health Risk |
Likely pathogenic |
MYRF-related disorder, MYRF-related disorder |